Depreotide

Depreotide is a peptide analogue of a somatostatin receptor that preferentially binds to somatostatin receptors 2, 3, and 5. Many lung tumors may express these receptors to a greater extent than normal tissue. Depreotide study is a noninvasive, receptor-specific imaging agent that is used to assess malignant versus benign single pulmonary nodules before biopsy.

Online Inquiry

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	10-101-102
CAS	161982-62-3
Background	Tc-99m labeled somatostatin receptor-binding peptide (Depreotide) has received US Food and Drug Administration approval for use in the imaging of suspected malignant tumors in the lung. This agent has been utilized in the evaluation of solitary pulmonary nodules and has shown a specificity of 73.1% to 88% and a sensitivity of 93% to 96.6% for detection of malignant solitary pulmonary nodules. The authors therefore concluded that Depreotide is a safe and useful method for the non-invasive evaluation of solitary pulmonary nodules with a sensitivity and accuracy comparable to that reported for FDG PET. >> Read More
Synonyms/Alias	NeoTec; P 829; P829; D03687; P-829
Chemical Name	(2S)-6-amino-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-3-[[2-[2-[(2S,5S,8S,11R,14S,17S)-14-(4-aminobutyl)-5-benzyl-8-[(4-hydroxyphenyl)methyl]-11-(1H-indol-3-ylmethyl)-4-methyl-3,6,9,12,15,18-hexaoxo-17-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]ethylsulfanyl]acetyl]amino]propanoyl]amino]hexanoyl]amino]-3-sulfanylpropanoyl]amino]hexanamide;technetium
M.F/Formula	C65H96N16O12S2
M.W/Mr.	1357.69
Sequence	Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl) (1-1')-sulfide with 3-((mercaptoacetyl)amino)-L-alanyl-L-lysyl-L-cysteinyl-L-lysinamide
Labeling Target	Somatostatin receptor
Application	Radiodiagnostic agent
Areas of Interest	Cancer treatment

CAT#	Product Name	M.W	Molecular Formula	Inquiry
10-101-100	Thymosin β15	5285.05	C225H377N59O80S3	Inquiry
10-101-122	Resveratrol	228.25	C14H12O3	Inquiry
10-101-124	Topotecan Hydrochloride	421.44	C23H23N3O5	Inquiry
10-101-177	Plitidepsin	1110.33858	C57H87N7O15	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Source#	Synthetic
Long-term Storage Conditions	−20°C
InChI	InChI=1S/C65H96N16O12S2/c1-38(2)55-64(92)76-49(26-30-95-37-54(83)72-35-44(69)57(85)74-47(20-10-13-28-67)58(86)79-52(36-94)62(90)73-46(56(70)84)19-9-12-27-66)65(93)81(3)53(32-39-15-5-4-6-16-39)63(91)78-50(31-40-22-24-42(82)25-23-40)60(88)77-51(33-41-34-71-45-18-8-7-17-43(41)45)61(89)75-48(59(87)80-55)21-11-14-29-68/h4-8,15-18,22-25,34,38,44,46-53,55,71,82,94H,9-14,19-21,26-33,35-37,66-69H2,1-3H3,(H2,70,84)(H,72,83)(H,73,90)(H,74,85)(H,75,89)(H,76,92)(H,77,88)(H,78,91)(H,79,86)(H,80,87)/t44-,46-,47-,48-,49-,50-,51+,52-,53-,55-/m0/s1
InChI Key	XXXSJQLZVNKRKX-YQRDHHIGSA-N
Canonical SMILES	CC(C)C1C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)CC5=CC=CC=C5)C)CCSCC(=O)NCC(C(=O)NC(CCCCN)C(=O)NC(CS)C(=O)NC(CCCCN)C(=O)N)N.[Tc]
Isomeric SMILES	CC(C)[C@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)CC5=CC=CC=C5)C)CCSCC(=O)NC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N)N
BoilingPoint	1654.2±65.0 °C at 760 mmHg
References	99mTc-depreotide uptake was found in 62 out of 66 malignancies, including 57 of 58 primary lung cancer cases. Two cases of lung metastasis (one from a colon cancer and one from an adenoid cystic carcinoma originating in the palate) and one rib chondrosarcoma did not show depreotide uptake. There were 33 patients with benign lesions, of whom 16 displayed false-positive 99mTc-depreotide uptake, whereof 11 were pneumonias. Tc-99m-depreotide uptake was absent in 17 patients with benign lesions, including all 10 hamartomas. The sensitivity in detecting malignancy was 94%, and in detecting lung cancer 98%. The specificity was calculated based on two sets of data. When all cases were used, the specificity was 52%. If the 12 pneumonias are excluded, the specificity was 77%. Axelsson, R., Herlin, G., Bååth, M., Aspelin, P., & Kölbeck, K. G. (2008). Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer. Acta Radiologica, 49(3), 295-302. Of 21 patients who had a focal high uptake of Depreotide, 17 were malignancies. One patient had two lesions with high Depreotide uptake, lung cancer, and pneumonia in the contralateral lung. Two patients with sarcoidosis and one with bilateral round atelectasis also had high Depreotide uptake bilaterally. Seven of the 8 patients with no uptake were true negative: 5 hamartomas and 2 round atelectases. One small lung cancer in the pleura sinus did not have Depreotide uptake. Bååth, M., Kölbeck, K. G., & Danielsson, R. (2004). Somatostatin receptor scintigraphy with 99mTc-Depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiologica, 45(8), 833-839. Tc-depreotide imaging has low sensitivity but is useful in a one-third of OctreoScan-negative patients, displaying significantly better uptake than In-pentetreotide in this patient group. It aids diagnosis by highlighting lesions not seen by OctreoScan and/or CT/MRI imaging, and can possibly identify a group of patients amenable to therapy with radionuclide agents, such as SOM230, targeting somatostatin receptor subtypes 2, 3 and 5. Shah, T., Kulakiene, I., Quigley, A. M., Warbey, V. S., Srirajaskanthan, R., Toumpanakis, C., ... & Caplin, M. E. (2008). The role of 99mTc-depreotide in the management of neuroendocrine tumours. Nuclear medicine communications, 29(5), 436-440.
Melting Point	N/A